nuelin sa
meda health sales ireland limited - theophylline - tablets - 250 milligram
rhinolast 0.1 %w/v nasal spray solution
meda health sales ireland limited - azelastine hydrochloride - nasal spray solution - 0.1 %w/v - antiallergic agents, excl. corticosteroids
rhinolast hayfever nasal 0.1 %w/v nasal spray solution
meda health sales ireland limited - azelastine hydrochloride - nasal spray solution - 0.1 %w/v - antiallergic agents, excl. corticosteroids
acupan film coated tablet 30 milligram
meda health sales ireland limited - nefopam hydrochloride - film coated tablet - 30 milligram
ascal oral powder 650 milligram
meda health sales ireland limited - carbasalate calcium calcium urea - oral powder - 650 milligram
acupan 30 milligram film coated tablet
meda health sales ireland limited - nefopam hydrochloride - film coated tablet - 30 milligram
ascal 650 milligram oral powder
meda health sales ireland limited - carbasalate calcium calcium urea - oral powder - 650 milligram
novantrone concentrate for soln for inf 2 mg/ml
meda health sales ireland limited - mitoxantrone hydrochloride - concentrate for soln for inf - 2 mg/ml
zamadol capsules hard 50 milligram
meda health sales ireland limited - tramadol hydrochloride - capsules hard - 50 milligram
leflunomide medac
medac gesellschaft für klinische spezialpräparate mbh - leflunomide - arthritis, rheumatoid - selective immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard).recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.